ReviewCureus2026
Clinical Effectiveness of Nebulized Magnesium Sulfate in Pediatric Acute Asthma: A Systematic Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a common cause of acute illness and healthcare utilization in children, and while intravenous magnesium sulfate is established in severe exacerbations, the clinical role of nebulized magnesium sulfate remains uncertain. This systematic review evaluated whether nebulized magnesium sulfate, used as an adjunct to standard therapy, improves clinical outcomes in pediatric acute asthma exacerbations. A comprehensive literature search was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) guidelines, identifying studies published between January 2010 and November 2025. Seven studies were included: six randomized controlled trials and one systematic review with meta-analysis, all involving pediatric populations. Study selection, data extraction, and quality appraisal were performed using validated tools, including A Measurement Tool to Assess Systematic Reviews (AMSTAR 2) and the Revised Cochrane Risk-of-Bias tool for randomised trials (RoB 2). Across the included studies, nebulized magnesium sulfate demonstrated variable and generally modest effects on asthma severity scores, with no consistent reduction in hospital admission rates, length of stay, or escalation of care. Safety findings were reassuring, with no serious treatment-related adverse events reported. Overall, current evidence does not demonstrate a clear or consistent additional clinical benefit of nebulized magnesium sulfate beyond standard therapy in pediatric acute asthma exacerbations. Future well-designed trials using standardized outcome measures and longer follow-up are required to clarify its role in contemporary pediatric asthma management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.